Pamela Cipriano, APRN
Acute Care · Thomaston, CTNPI 1679850408
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.5% of the total across 237 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,486 and has fallen 70.0% since, to $446 in 2025. Among acute care clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 237 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$980
- GSK$418
- Lilly USA, LLC$338
- Otsuka America Pharmaceutical, Inc.$316
- AstraZeneca$286
- Lundbeck LLC$266
- plus $2K from 23 others
What the payments were for
- Consulting fees$1754%
- Food & beverage$4,01491%
- Education$1985%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 68 | $980 |
| GSK | 19 | $418 |
| Lilly USA, LLC | 16 | $338 |
| Otsuka America Pharmaceutical, Inc. | 18 | $316 |
| AstraZeneca | 14 | $286 |
| Lundbeck LLC | 13 | $266 |
| Amgen | 3 | $225 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $196 |
| Idorsia Pharmaceuticals US Inc | 10 | $162 |
| Orexo US, Inc. | 9 | $146 |
| Boehringer Ingelheim | 7 | $134 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $132 |
| Amneal Pharmaceuticals LLC | 5 | $90 |
| Novo Nordisk | 5 | $85 |
| Johnson & Johnson | 4 | $77 |
| Alkermes, Inc. | 4 | $71 |
| Biohaven Pharmaceuticals, Inc. | 2 | $55 |
| QOL Medical, LLC | 3 | $54 |
| Eisai Inc. | 3 | $52 |
| Indivior Inc. | 3 | $51 |
| E.r. Squibb & Sons, L.L.C. | 2 | $50 |
| Exact Sciences | 2 | $49 |
| Astellas Pharma US Inc | 3 | $47 |
| Pfizer | 2 | $32 |
| IBSA Pharma Inc. | 1 | $19 |
| Braeburn Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $14 |
| Phadia US Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$175
How this compares
$4,388 in reported general payments places this provider in the 95th percentile of 239 acute care providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 16 | $24,777 |
| EliquisApixaban | 21 | $23,375 |
| OxycontinOxycodone Hcl | 13 | $21,753 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 14 | $17,077 |
| RybelsusSemaglutide | 14 | $13,324 |
| MounjaroTirzepatide | 12 | $10,482 |
| MyrbetriqMirabegron | 14 | $10,319 |
| BelsomraSuvorexant | 16 | $9,670 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,116 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,127 |
| SynthroidLevothyroxine Sodium | 42 | $4,112 |
| Levemir FlexpenInsulin Detemir | 13 | $2,329 |
| Testosterone | 12 | $1,531 |
| Levothyroxine Sodium | 86 | $1,054 |
| Liothyronine Sodium | 17 | $910 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $85 | $38,10130 claims |
| PfizerEliquis | $32 | $23,37521 claims |
| Orexo US, Inc.Zubsolv | $146 | $17,07714 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $418 | $12,24323 claims |
| Lilly USA, LLCMounjaro | $338 | $10,48212 claims |
| Astellas Pharma US IncMyrbetriq | $47 | $10,31914 claims |
| AbbVieSynthroid | $980 | $4,11242 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $90 | $1,05486 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 239 acute care providers in Connecticut.
Other acute care in Thomaston
- Hassen BorhotManchester$75K
- Terea GuimaraesBranford$36K
- Rosanna MenditeHartford$11K
- Nicola CalabreseMiddletown$9K
- Mary CicchettiHartford$7K
- Daniel MeewesHartford$7K
- Tara HalpinWethersfield$6K
- Wayne RockhillWaterbury$5K
- Katrina CarotenutiWaterbury$5K
- Caryn EckerNorwalk$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.